At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy

Clinical Review for Basic Researchers: Treating patients with CTLA‐4 and PD‐1 pathway blocking antibodies, plus clinical progress and application of agents in earlier stages of development. It is increasingly appreciated that cancers are recognized by the immune system, and under some circumstances,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of leukocyte biology Vol. 94; no. 1; pp. 41 - 53
Main Authors: Callahan, Margaret K., Wolchok, Jedd D.
Format: Journal Article
Language:English
Published: United States Society for Leukocyte Biology 01.07.2013
Subjects:
Antibodies, Blocking - therapeutic use
Clinical Trials as Topic
CTLA-4 Antigen - antagonists & inhibitors
CTLA-4 Antigen - immunology
endpoints
Humans
Immunotherapy
Neoplasms - immunology
Neoplasms - therapy
overall survival
Paired Basic-Translational Reviews
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Programmed Cell Death 1 Receptor - immunology
tumor
overall survival
endpoints
tumor
ISSN:0741-5400, 1938-3673, 1938-3673
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical Review for Basic Researchers: Treating patients with CTLA‐4 and PD‐1 pathway blocking antibodies, plus clinical progress and application of agents in earlier stages of development. It is increasingly appreciated that cancers are recognized by the immune system, and under some circumstances, the immune system may control or even eliminate tumors. The modulation of signaling via coinhibitory or costimulatory receptors expressed on T cells has proven to be a potent way to amplify antitumor immune responses. This approach has been exploited successfully for the generation of a new class of anticancer therapies, “checkpoint‐blocking” antibodies, exemplified by the recently FDA‐approved agent, ipilimumab, an antibody that blocks the coinhibitory receptor CTLA‐4. Capitalizing on the success of ipilimumab, agents that target a second coinhibitory receptor, PD‐1, or its ligand, PD‐L1, are in clinical development. Lessons learned from treating patients with CTLA‐4 and PD‐1 pathway‐blocking antibodies will be reviewed, with a focus on concepts likely to inform the clinical development and application of agents in earlier stages of development. See related review At the bench: Preclinical rationale for CTLA‐4 and PD‐1 blockade as cancer immunotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0741-5400
1938-3673
1938-3673
DOI:10.1189/jlb.1212631